Présentation de l'entreprise
Genprex, Inc. operates as a clinical-stage gene therapy company dedicated to the development of novel therapeutic solutions for patients suffering from cancer and diabetes. The firm's technological platform is engineered to administer disease-fighting genes, thereby creating new treatment modalities specifically targeted at these patient populations. Operating within the healthcare sector and the biotechnology industry, the company leverages advanced biological research to address significant unmet medical needs. With a market capitalization of $11.85 million and an employee base of 13, the organization maintains a highly specialized but limited operational footprint. These valuation figures indicate that the company exists in the early-to-mid stage of its lifecycle, where asset value is derived primarily from intellectual property and clinical potential rather than established commercial revenue streams. The absence of significant revenue generation at this stage is consistent with the capital-intensive nature of biotechnology firms focused on clinical-stage programs, suggesting that the current market capitalization reflects high-risk, high-reward expectations regarding future product approvals.
Santé financière
The company reports negative net income of $-16,228,953 and negative EBITDA of $-15,508,926 over the trailing twelve months, with revenue data listed as unavailable in the current reporting period. The substantial gap between reported revenue (which is effectively zero or negligible given the N/A status) and the heavy net losses reveals a cost structure dominated by research and development expenditures typical of clinical-stage ventures. Free cash flow stands at $-10,226,542, indicating that the company is burning cash to fund its clinical trials and operational overhead, which limits its immediate financial flexibility and reliance on external capital markets. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, a figure that reflects the lack of commercial sales volume necessary to generate a positive contribution margin or operational profitability. On the liability side, the company holds $7.83 million in cash against $0 in debt, creating a net cash position that provides a buffer against dilution but does not yet generate interest coverage. The debt-to-equity ratio is listed as N/A due to the absence of debt and equity values suitable for this calculation, yet the balance sheet remains conservative given the zero leverage. Liquidity is robust with a current ratio of 3.84, signifying that the company possesses sufficient current assets to cover its short-term obligations more than three times over. Return on Equity is severely negative at -338.7%, while Return on Assets is -135.8%, metrics that collectively reveal that management is currently deploying capital to generate losses rather than returns, a standard but financially demanding phase for pre-commercial biotech entities.
Évaluation de la valorisation
Valuation multiples for Genprex, Inc. are distorted by its lack of earnings, with a trailing P/E ratio listed as N/A and a forward P/E of -0.60. The discrepancy between an unavailable trailing P/E and a negative forward P/E implies that the market is pricing in a future trajectory where earnings may eventually turn positive, although the negative forward multiple currently suggests an expectation of continued losses or a mathematical artifact of negative earnings. The price-to-book ratio is 0.35, indicating that the stock trades at a significant discount to its book value, which often reflects market skepticism regarding the recoverable value of the company's tangible assets versus its intangible clinical pipeline. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are also unavailable or negative (EV/EBITDA at -0.26), suggesting that traditional valuation frameworks do not apply and that investors are relying on clinical milestones rather than financial performance. The 52-week high is $55.00 and the 52-week low is $1.26, a range that highlights extreme volatility; without a specific current price provided in the facts, the trading range itself illustrates the speculative nature of the equity. The beta of -0.67 is anomalous for equities and indicates an inverse correlation with the broader market, suggesting that price movements of GNPX move in the opposite direction of the market index, a characteristic that increases idiosyncratic risk.
Growth & Income
Revenue growth and earnings growth rates are both listed as N/A, preventing a direct comparison of whether earnings are growing faster or slower than revenue, as no positive baseline revenue exists to establish a growth rate. Since the company does not pay a dividend, the dividend yield is N/A and the payout ratio is 0.0%, confirming that the firm reinvests all available resources, including its cash reserves, back into its clinical programs and research operations rather than distributing income to shareholders. This reinvestment strategy is necessitated by the high capital requirements of developing gene therapies for cancer and diabetes, where funding clinical trials is a prerequisite for any future commercial success. Consequently, the overall growth and income profile is characterized by a complete absence of current income generation and measurable historical growth rates, relying entirely on the successful execution of its clinical-stage gene therapy programs to achieve future commercialization and profitability.